Anti-Cancer Antibodies
Anticancer antibodies has created great interest in antibody-based therapeutics for hematopoietic malignant neoplasms and solid tumors. Given the likelihood of lower toxic effects of antibodies that target tumor cells and have limited impact on nonmalignant bystander organs vs small molecules, the potential increased efficacy by conjugation to radioisotopes and other cellular toxins, and the ability to characterize the target with clinical laboratory diagnostics to improve the drug's clinical performance, current and future antibody therapeutics are likely to find substantial roles alone and in combination therapeutic strategies for treating patients with cancer. Therapeutic antibodies have become a major strategy in clinical oncology owing to their ability to bind specifically to primary and metastatic cancer cells with high affinity and create antitumor effects by complement-mediated cytolysis and antibody-dependent, cell-mediated cytotoxicity (naked antibodies) or by the focused delivery of radiation or cellular toxins (conjugated antibodies).
- Antibodies in Treatment of Cancer
- Characterizing and clinical use of Circulating Tumor Cells (CTCS)
- Advances in tumor modeling, cancer drug discovery and development
- Translational approaches in cancer immunotherapy development
- Innovative in vitro and in vivo modeling
Related Conference of Anti-Cancer Antibodies
5th International conference on Vaccines, Vaccination and Immunization
19th International Conference on Allergy and Clinical Immunology
5th International Conference on Immunology And Immunotherapy
Anti-Cancer Antibodies Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibiotics
- Antibiotics used in Industries
- Antibiotics: Advances in Treatment
- Antibiotics: Applications
- Antibiotics: Clinical Trials
- Antibiotics: Infectious Diseases
- Antibiotics: Mechanism of Action
- Antibodies: Infectious Diseases
- Antibodies: Medical Applications
- Antibody Conjugate Therapeutics: Challenge and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Humanization Technologies
- Auto Immune Antibodies
- Bio therapeutics : Early Analytical Development
- Bio Therapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio Therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing(NGS) in Antibody Discovery and Engineering: Overview and Applications
- Protein Engineering and Genetic Engineering
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)